BN Business News
Add your company to Business Communicator →

Business · 17/11/20261 min read

Five-year data of continuous Leqembi® treatment show increasing benefit over time

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

STOCKHOLM, Nov. 17, 2026 — BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term extension, showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer's...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →